Harrow (HROW)

• Market cap: $1.2B
• 1 day: -0.53%
• 5 days: -3.78%
• 1 month: -19.57%
• 3 months: -26.31%
• 6 months: 57.50%
• Year to date: 183.10%
• 1 year: 214.70%
• 5 years: 364.06%
• 10 years: 335.39%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.

Employees: 217

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

445% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 11

136% more capital invested

Capital invested by funds: $399M [Q2] → $940M (+$541M) [Q3]

45% more funds holding

Funds holding: 109 [Q2] → 158 (+49) [Q3]

4.94% more ownership

Funds ownership: 53.98% [Q2] → 58.92% (+4.94%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

4% less call options, than puts

Call options by funds: $42M | Put options by funds: $43.8M

5% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 41

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $55 63% upside
• Avg. target: $60 77% upside
• High target: $65 92% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Brooks O'Neil 45% 1-year accuracy 5 / 11 met price target	63% upside $55	Buy Maintained	4 Oct 2024
Craig-Hallum Chase Knickerbocker 43% 1-year accuracy 10 / 23 met price target	92% upside $65	Buy Maintained	4 Oct 2024